{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-060001","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.872861+00:00","generated_at":"2026-06-05T02:42:31.696750+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Wave Life Sciences reports FY2023 revenue $113.3M; cash runway into Q4 2025; INHBE candidate selected","bullets":["Cash and equivalents $200.4M at Dec 31, 2023; additional $34M received in Q1 2024; runway expected into Q4 2025.","Full-year revenue $113.3M (2022: $3.6M) driven by GSK and Takeda collaborations; net loss improved to $57.5M from $161.8M.","INHBE lead clinical candidate for obesity selected; GalNAc-siRNA shows potent silencing, weight loss without muscle loss; trial initiation expected Q1 2025.","Proof-of-mechanism data for WVE-006 in AATD expected 2024; WVE-N531 dystrophin data in DMD expected Q3 2024; WVE-003 multi-dose HD data expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-060001","json":"https://secwatch.observer/filing/0001193125-24-060001.json","markdown":"https://secwatch.observer/filing/0001193125-24-060001.md","text":"https://secwatch.observer/filing/0001193125-24-060001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312524060001/0001193125-24-060001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312524060001/d761944d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:42:31.696750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}